CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announces that Dante Picazo, Chief Executive Officer of the Company, has designated 500,000,000 shares of common stock from his personal holdings to honor the directors, employees, and key associates whose dedication, loyalty, and work have helped shape CBIH's journey and strengthen the Company through years
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-06 7:00 AM EDT | Cannabis Bioscience International Holdings
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications LOI includes minimum annual purchase commitments in Year 1 Expands TempraMed's footprint across the Middle East and supports broa
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-06 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Delivers US$51.6 Million Proforma Annualized Revenue Run-Rate in Q1-2026
For the three months ended March 31, 2026, Custom Health achieved quarterly revenue of US$4.3 million, while InnovativeRx (as defined below) achieved record quarterly revenue of US$8.6 million, reflecting total consolidated quarterly revenue of US$12.9 million and proforma annualized revenue run-rate(1) of US$51.6 million. Custom Health successfully completed its public listing and started trading on the Toronto Stock Exchange on June 24,
Technologies, Pharmaceutique, Santé
2026-07-03 6:00 AM EDT | Custom Health Holdings Inc.
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m. Eastern Daylight Time Live Presentation: Available on Kiora's Investor Relations homepage at ir.ki
Biotechnologies, Pharmaceutique
2026-07-02 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Herbal Dispatch Announces Vesting of RSUs and Satisfaction of Certain Outstanding Fees
Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is providing this update in furtherance to its news release dated January 2, 2026, whereby it announced the granting in aggregate of 2,760,000 restricted share units ("RSUs"). The RSUs which were granted to certain officers, directors, employees, and consultants of the Company pursuant to the Company's
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-07-02 3:01 AM EDT | Herbal Dispatch Inc.
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("P
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-06-30 4:30 PM EDT | Theralase Technologies Inc.
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the la
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-06-30 3:05 AM EDT | TempraMed Technologies Ltd.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026"). Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-29 4:29 PM EDT | Elite Pharmaceuticals, Inc.
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporati
Biotechnologies, Pharmaceutique, Commerce de détail
2026-06-29 7:15 AM EDT | PharmaCorp RX Inc.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks a
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-06-26 4:10 PM EDT | TempraMed Technologies Ltd.
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at
Biotechnologies, Pharmaceutique, Santé
2026-06-26 8:47 AM EDT | Hemostemix Inc.
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has completed two significant milestones on its projected path to market scale and operational excellence. United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, which the Company believes are among the most pow
2026-06-26 8:00 AM EDT | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
Gaithersburg, Maryland--(Newsfile Corp. - June 25, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining and digital infrastructure company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has initiated an evaluation of proprietary data centre and power generation opportunities designed to support long-term DOGE mining operations and future AI infrastructure workloads. Alongside this exploration, t
2026-06-25 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in
2026-06-25 8:00 AM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Strategic Leadership Appointments to Support Continued Growth and Regulatory Excellence
Robert Guzman has been appointed Chief Compliance & Regulatory Officer, bringing extensive experience in regulatory oversight, compliance management, and quality assurance to strengthen Custom Health's governance framework and support the Company's continued expansion across highly regulated healthcare and pharmacy markets. Brent Herman, Founder, President and Chief Executive Officer of InnovativeRx US Holdings, Inc., has been appointed Executive Vice President, Cor
Technologies, Pharmaceutique, Santé
2026-06-25 6:30 AM EDT | Custom Health Holdings Inc.
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations to Attend Fastmarkets Global Lithium, Battery & Critical Materials in Las Vegas
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to announce that it will be attending the Fastmarkets Global Lithium, Battery & Critical Materials conference in Las Vegas, Nevada from June 23-2
Technologies, Produits chimiques, Pharmaceutique
2026-06-23 8:00 AM EDT | Telescope Innovations Corp.